-
Je něco špatně v tomto záznamu ?
The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers
Marie Stiborová, Eva Frei, Volker M. Arlt, Heinz H. Schmeiser
Jazyk angličtina Země Česko
Typ dokumentu přehledy
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
- MeSH
- adukty DNA metabolismus MeSH
- aktivace enzymů MeSH
- biotransformace MeSH
- cytochrom P-450 CYP1A1 metabolismus MeSH
- cytochrom P-450 CYP1A2 metabolismus MeSH
- financování organizované MeSH
- kyseliny aristolochové farmakokinetika toxicita MeSH
- ledviny účinky léků MeSH
- lidé MeSH
- myši MeSH
- NADPH-cytochrom c-reduktasa metabolismus MeSH
- nemoci ledvin chemicky indukované MeSH
- urologické nádory chemicky indukované metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- přehledy MeSH
BACKGROUND: Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy (AAN), which is characterized by chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause another type of kidney fibrosis with malignant transformation of the urothelium, called Balkan Endemic Nephropathy (BEN). The compound predominantly responsible for the nephropathy and urothelial cancer of AA, is aristolochic acid I (AAI) which is a genotoxic mutagen after metabolic activation The activation pathway involves reduction of the nitro group to a cyclic N-acylnitrenium ion that can form covalent DNA adducts. These specific DNA adducts have been detected in experimental animals exposed to AAI, and in urothelial tissues from AAN patients. In rodent tumours induced by AAI, 7-(deoxyadenosin-N(6)-yl)aristolactam I was the most abundant DNA adduct formed and associated with activation of ras oncogenes through a characteristic transversion mutation. Such A:T-->T:A mutations have been identified in TP53 of urothelial tumour DNA of an AAN patient and in several patients suffering from BEN along with specific AA-DNA adducts. Understanding which enzymes are involved in AAI activation to species forming DNA adducts and/or detoxification to its O-demethylated metabolite aristolochic acid Ia (AAIa) is important in order to assess susceptibility to this carcinogen. METHODS AND RESULTS: A literature search. CONCLUSIONS: The most important human enzymes activating AAI by simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 (CYP) 1A2 and renal microsomal NADPH:CYP reductase as well as cyclooxygenase which is highly expressed in urothelial tissue. However, the contribution of most of these enzymes to the development of AAN and BEN diseases is still unclear. Hepatic CYP enzymes were found to detoxify AAI to AAIa in mice, and thereby protect the kidney from injury. CYP enzymes of the 1A subfamily seem to play a major role in this process in mouse liver. Likewise, among human CYP enzymes, CYP1A1 and 1A2 were found to be the most efficient enzymes participating in AAI oxidation to AAIa in vitro. Nevertheless, which CYPs are the most important in this process in both animal models and in humans have not been entirely resolved as yet. In addition, the relative contribution of enzymes found to activate AAI to species responsible for induction of urothelial cancer in humans remains still to be resolved.
Citace poskytuje Crossref.org
Lit.: 54
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10018501
- 003
- CZ-PrNML
- 005
- 20111210182752.0
- 008
- 100901s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2009.001 $2 doi
- 035 __
- $a (PubMed)19365519
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Stiborová, Marie, $d 1950-2020 $7 jo2005259907
- 245 14
- $a The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers / $c Marie Stiborová, Eva Frei, Volker M. Arlt, Heinz H. Schmeiser
- 314 __
- $a Department of Biochemistry, Faculty of Sciences, Charles University, Prague
- 504 __
- $a Lit.: 54
- 520 9_
- $a BACKGROUND: Ingestion of aristolochic acid (AA) is associated with the development of aristolochic acid nephropathy (AAN), which is characterized by chronic renal failure, tubulointerstitial fibrosis and urothelial cancer. AA may also cause another type of kidney fibrosis with malignant transformation of the urothelium, called Balkan Endemic Nephropathy (BEN). The compound predominantly responsible for the nephropathy and urothelial cancer of AA, is aristolochic acid I (AAI) which is a genotoxic mutagen after metabolic activation The activation pathway involves reduction of the nitro group to a cyclic N-acylnitrenium ion that can form covalent DNA adducts. These specific DNA adducts have been detected in experimental animals exposed to AAI, and in urothelial tissues from AAN patients. In rodent tumours induced by AAI, 7-(deoxyadenosin-N(6)-yl)aristolactam I was the most abundant DNA adduct formed and associated with activation of ras oncogenes through a characteristic transversion mutation. Such A:T-->T:A mutations have been identified in TP53 of urothelial tumour DNA of an AAN patient and in several patients suffering from BEN along with specific AA-DNA adducts. Understanding which enzymes are involved in AAI activation to species forming DNA adducts and/or detoxification to its O-demethylated metabolite aristolochic acid Ia (AAIa) is important in order to assess susceptibility to this carcinogen. METHODS AND RESULTS: A literature search. CONCLUSIONS: The most important human enzymes activating AAI by simple nitroreduction in vitro are hepatic and renal cytosolic NAD(P)H:quinone oxidoreductase, hepatic microsomal cytochrome P450 (CYP) 1A2 and renal microsomal NADPH:CYP reductase as well as cyclooxygenase which is highly expressed in urothelial tissue. However, the contribution of most of these enzymes to the development of AAN and BEN diseases is still unclear. Hepatic CYP enzymes were found to detoxify AAI to AAIa in mice, and thereby protect the kidney from injury. CYP enzymes of the 1A subfamily seem to play a major role in this process in mouse liver. Likewise, among human CYP enzymes, CYP1A1 and 1A2 were found to be the most efficient enzymes participating in AAI oxidation to AAIa in vitro. Nevertheless, which CYPs are the most important in this process in both animal models and in humans have not been entirely resolved as yet. In addition, the relative contribution of enzymes found to activate AAI to species responsible for induction of urothelial cancer in humans remains still to be resolved.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyseliny aristolochové $x farmakokinetika $x toxicita $7 D034341
- 650 _2
- $a biotransformace $7 D001711
- 650 _2
- $a cytochrom P-450 CYP1A1 $x metabolismus $7 D019363
- 650 _2
- $a cytochrom P-450 CYP1A2 $x metabolismus $7 D019388
- 650 _2
- $a adukty DNA $x metabolismus $7 D018736
- 650 _2
- $a aktivace enzymů $7 D004789
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x účinky léků $7 D007668
- 650 _2
- $a nemoci ledvin $x chemicky indukované $7 D007674
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a NADPH-cytochrom c-reduktasa $x metabolismus $7 D009251
- 650 _2
- $a urologické nádory $x chemicky indukované $x metabolismus $7 D014571
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Frei, Eva. $7 _AN036392
- 700 1_
- $a Arlt, Volker M. $7 xx0074763
- 700 1_
- $a Schmeiser, Heinz H.
- 773 0_
- $w MED00012606 $t Biomedical papers $g Roč. 153, č. 1 (2009), s. 5-11 $x 1213-8118
- 856 41
- $u http://biomed.papers.upol.cz/pdfs/bio/2009/01/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 7
- 990 __
- $a 20100830113932 $b ABA008
- 991 __
- $a 20100903123007 $b ABA008
- 999 __
- $a ok $b bmc $g 767527 $s 631436
- BAS __
- $a 3
- BMC __
- $a 2009 $b 153 $c 1 $d 5-11 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $x MED00012606
- LZP __
- $a 2010-22/mkme